Methods and compositions for bone formation

Patent metadata

Field	Value
Publication number	US-9981010-B2
Application number	US-201514594701-A
Country	US
Kind code	B2
Filing date	Jan 12, 2015
Priority date	Dec 1, 2009
Publication date	May 29, 2018
Grant date	May 29, 2018

Abstract

A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects.

First claim

What is claimed is:

1. A method to induce spinal fusion in a mammal, said method comprising the step of:
locally delivering to a spine of a mammal cells transduced with a virus containing nucleic acids encoding a bone morphogenetic protein, said cells encapsulated in poly(ethylene glycol) diacrylate (PEG-DA) hydrogel microsphere, wherein upon said delivering said spinal fusion is induced and wherein said at least one hydrogel microsphere is formed by:
forming a hydrogel precursor solution by combining PEG-DA with triethanolamine/HEPES buffered saline, 1-vinyl-2-pyrrolidinone, eosin Y, and said cells;
forming a mineral oil solution by combining acetophenone, 1-vinyl-2-pyrrolidinone, and mineral oil;
combining said hydrogel precursor solution with said mineral oil solution; and
emulsifying said combined solution,
wherein said at least one microsphere contains up to 100 of said cells.

2. The method of claim 1 , wherein the cells are configured to produce bone morphogenetic protein-2 by transducing the cells with at least one viral vector having nucleic acids encoding a human bone morphogenetic protein-2.

3. The method of claim 2 wherein the at least one vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, and a combination thereof.

4. The method of claim 3 wherein the one or more viral vectors are rendered replication defective.

5. The method of claim 3 , wherein the cells are selected from the group consisting of fibroblast cells, mesenchymal stem cells, and a combination thereof.

6. The method of claim 1 , wherein said local delivery to the targeted site of the mammal is via a syringe.

7. The method of claim 1 , wherein said local delivery to the targeted site of the mammal is intramuscular.

8. The method of claim 1 , wherein the microsphere provides for a minimal immune reaction by said mammal to said cells.

Assignees

• Baylor College Medicine
• Univ Rice William M

Inventors

• Davis Alan R
• Davis Elizabeth A
• Moran Kevin
• Olabisi Ronke M
• West Jennifer L
• Franco Christy

Classifications

• A61K38/1875 Primary

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• C12N2533/30

  Synthetic polymers · CPC title

• C07K14/51

  Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• C12N5/0652

  Cells of skeletal and connective tissues; Mesenchyme · CPC title